← Leaderboards
Stanley Ballou
Case Western Reserve University
$19,199
Attributed
$19,199
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$19,199 · 3
By mechanism
M01$19,199 · 3
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Paul R Carey$6,813,776
- Stephen S Macintyre$0
- Hillard M Lazarus$3,198,402
- Masao Ikeda-Saito$666,341
- Paula Bekeny Usis$0
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationClinical ResearchHuman SubjectHuman Therapy EvaluationDrug Administration Rate /DurationSystemic Lupus ErythematosusAntinuclear AutoantibodyLongitudinal Human StudyNaproxenNonsteroidal Antiinflammatory AgentOligonucleotidesOsteoarthritisOxidoreductase InhibitorPlacebosProstaglandin Endoperoxide SynthaseSpine DisorderKneeArthritis TherapyChemical ConjugateConnective Tissue Disorder ChemotherapyGastrointestinal Drug AbsorptionHand
Grant awards (9)
REPEATED DOSES OF LPJ-394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
An open label of LJP394 in patients with systemic lupus erythematosus$0
M01 · FY2002 · RR
Tolerability &effectiveness of rofecoxib vs naproxen$0
M01 · FY2002 · RR
An open label of LJP394 in patients with systemic lupus erythematosus$0
M01 · FY2001 · RR
REPEATED DOSES OF LPJ-394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
Tolerability &effectiveness of rofecoxib vs naproxen$0
M01 · FY2001 · RR
REPEATED DOSES OF LPJ-394 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$19,199
M01 · FY2000 · RR
Tolerability &effectiveness of rofecoxib vs naproxen$0
M01 · FY2000 · RR
An open label of LJP394 in patients with systemic lupus erythematosus$0
M01 · FY2000 · RR